Medical Director Articles

The term "article" is used to describe any bulletin article, web site article, educational handout or any other non-LCD document intended for public release that contains coverage/coding statements or medical review related billing or claims considerations.

Articles address local coverage, coding or medical review related billing and claims considerations, and may include any newly developed educational materials, coding instructions or clarification of existing medical review related billing or claims policy.

The article listing will continue to expand as additions are made.

Last Updated Jan 30 , 2024
Articles Source Posted
Billing and Coding: MolDX: Microsatellite Instability-High (MSI-H) and Mismatch Repair Deficient (dMMR) Biomarker for Patients with Unresectable or Metastatic Solid Tumors (A56103) - R4 - Effective January 1, 2024 Feb 01, 2024
Billing and Coding: Minimal Residual Disease Testing for Hematologic Cancers (A58996) - R5 - Effective January 1, 2024 Feb 01, 2024
Billing and Coding: MolDX: DecisionDX-Melanoma (A57417) Retirement - Effective August 8, 2022 Jan 25, 2024
Sacroiliac Joint Injections and Procedures (A59244) - R4 - Effective January 25, 2024 Jan 25, 2024
Billing and Coding: MolDX: Pharmacogenomics Testing (A57384) - R13 - Effective January 25, 2024 Jan 25, 2024
Billing and Coding: MolDX: Plasma-Based Genomic Profiling in Solid Tumors (A58973) - R4 - Effective January 1, 2024 Jan 25, 2024
Billing and Coding: MolDX: Molecular Diagnostic Tests (MDT) (A57526) - R17 - Effective January 1, 2024 Jan 25, 2024
Proposed Local Coverage Determinations - Published for Review and Comments Jan 18, 2024
Billing and Coding: MolDX: Next-Generation Sequencing for Solid Tumors (A57901) - R6 - Effective January 1, 2024 Jan 18, 2024
Billing and Coding: MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies (A57891) - R7 - Effective January 1, 2024 Jan 18, 2024
Billing and Coding: MolDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer (A58181) - R7 - Effective January 1, 2024 Jan 18, 2024
Local Coverage Determinations (LCDs) Finalized - Effective February 25, 2024 Jan 15, 2024
Billing and Coding: MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers (A58454) - R6- January 1, 2024 Jan 11, 2024
Billing and Coding: MolDX: Molecular Diagnostic Tests (MDT) (A57526) - R16- January 1, 2024 Jan 11, 2024
Billing and Coding: MolDX: Repeat Germline Testing (A57331) - R10 - January 1, 2024 Jan 11, 2024
Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing (A58720) - R15 - January 1, 2024 Jan 11, 2024
Billing and Coding: MolDX: Fragile X (A55241) - R6 - January 1, 2024 Jan 11, 2024
Billing and Coding: MolDX: Proteomics Testing (A59641) - Effective January 31, 2024 Jan 04, 2024
Billing and Coding: Implantable Infusion Pumps for Chronic Pain (A55239) - R16 - Effective January 1, 2024 Jan 04, 2024
2024 CPT/HCPCS Local Coverage Article (LCA) Updates Dec 28, 2023